More than 6.3% of households in Great Britain now include at least one GLP-1 user, according to the research by Worldpanel by Numerator
If a study is near you, contact the site coordinator listed under "Contacts and Locations." Expect a pre-screen call, a screening visit, and an eligibility decision before enrollment
Ridker PM, Devalaraja M, Baeres FMM et al (2021) IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial
In contrast, Bydureon is a long-acting, once-weekly formulation, developed using a microsphere-based delivery system
Verify your specific benefits with Cigna or through Klaritys benefits check before booking